Abstract
Bariatric surgery is increasingly performed in morbidly obese HIV patients. Limited data exist regarding antiretroviral drug exposure after bariatric surgery. We report a case of a morbidly obese HIV patient who underwent sleeve gastrectomy. Abacavir, lamivudine, and dolutegravir therapeutic drug monitoring was performed at several time points pre- and postsurgery. Significantly increased levels were measured, particularly for abacavir, whose levels increased ~12-fold. Several mechanistic explanations for these findings are discussed.
| Original language | English |
|---|---|
| Article number | e02453-19 |
| Journal | Antimicrobial Agents and Chemotherapy |
| Volume | 64 |
| Issue number | 4 |
| DOIs | |
| State | Published - 2020 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:Copyright © 2020 American Society for Microbiology. All Rights Reserved.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Antiretrovirals
- Bariatric surgery
- Obesity
- Sleeve gastrectomy
Fingerprint
Dive into the research topics of 'Case report of increased exposure to antiretrovirals following sleeve gastrectomy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver